The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Big news imo.
For immediate release
20 May 2022
ANGLE plc ("the Company")
PROSTATE CANCER UK FUNDS NEW STUDY USING PARSORTIX
Research into the use of Parsortix-based CTC blood test to assess whether prostate cancer patients require prostatectomy surgery
Potential for a new standard of care in an area of high unmet medical need
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that Prostate Cancer UK has approved funding for a significant clinical study at Barts Cancer Institute, Queen Mary University of London. The study will investigate the use of the Parsortix® system to isolate circulating tumour cells (CTCs) as a predictor of future disease recurrence. Assessment of whether prostate cancer is likely to progress, if this can be done reliably, may have a major bearing on whether radical prostatectomy surgery is the most appropriate treatment choice.
The trial is being funded by a £750,000 grant from Prostate Cancer UK and will follow 200 men with localised prostate cancer over five years. The aim of the study is to see whether the presence of mesenchymal CTCs and CTC clusters in peripheral blood, assessed using the Parsortix system, can predict whether the cancer will eventually spread. The study has been designed and will be conducted by Barts Cancer Institute and is being funded by Prostate Cancer UK, both independently from ANGLE. ANGLE has agreed to provide support for the study through the provision of Parsortix instruments, cassettes and reagents.
The study will enrol patients who are due to have radical prostatectomy surgery and will track them during and after treatment. The researchers will take a blood sample before and at regular intervals after the surgery and process the samples using the Parsortix system seeking to identify those patients where disease progression subsequently occurs. The design of this study has been informed by earlier pilot studies independently conducted at Barts Cancer Institute using the Parsortix system.
The trial is blinded, so the doctors treating the patients will not know the outcome of the blood tests. If the Parsortix system can be used to provide a predictive assessment of disease progression despite radical prostatectomy, it could have a significant impact on how prostate cancer is treated, making it easier for doctors to choose the correct and most effective treatment option.
It sounds like they need something that can capture cancer cells in blood. Unfortunately the whole article is too long to paste here in full.
'He does have to explain, though, that despite their success over the past year, whether it works in practice is still far from known. There are two significant reasons why a cancer vaccine is so much harder than one against coronavirus. The first is that the cancer is already there. “If you have a relatively small tumour of one centimetre size, it’s about 500 million to 1 billion cells. And this tumour continues to grow. It’s a race against time,” he says.
This is why they are looking in people who have had their cancer removed by surgery. Even then, to prevent its return, to kill the cancer cells still in the bloodstream, will take a huge immune response. Their vaccine schedule will not be merely the two doses and booster of the coronavirus vaccine: the patients will be given eight.
The second problem is more fundamental, and the reason why only now does the technology exist to — perhaps — make one work. There is no such thing as a strain of breast cancer like there is a strain of coronavirus. Each cancer is individual. This means that the vaccine needs to be individual too — made afresh, on the basis of each person’s tumour.
Only now, with “platform” technologies that use genetic code like a programming language, is this feasible. Scientists can take the genetic sequence of the cancer, pick the mutated protein they want to tackle and then — by hijacking the body’s own cells through the mRNA vaccine — churn out copies of it.
“My vision is that after surgery everyone at risk of a relapse receives a cancer vaccine and the risk is diminished to a minimum,” Sahin says. “And what we would like to establish is that this works for many different tumour types — that this could be a universal treatment.” All of which still, admittedly, sounds a bit like magic. But then, a year ago so did the idea of making a new pandemic vaccine in under a year'.
https://www.thetimes.co.uk/article/biontech-cancer-vaccine-trial-hopes-to-do-something-magic-5l82dhjm6
I've got no time for AO after their CEO took the **** out of Currys when they floated. Would love to see them fail.
Men whose prostate cancers are becoming resistant to a commonly used chemotherapy drug could be identified using regular blood tests, research suggests.
The study, presented at the National Cancer Research Institute festival, raises the prospect of sparing patients painful biopsies and enabling a switch to more effective therapies.
Men with prostate cancer that has started spreading to other parts of the body, and which does not respond to standard therapy, often receive docetaxel to boost their survival chances.
Caitlin Davies, a PhD research student at Barts Cancer Institute, Queen Mary University of London, and colleagues looked at markers of cancer in the blood known as circulating tumour cells (CTCs), which are shed into the bloodstream.
Davies and her colleagues found that certain patterns of CTCs could predict men’s chances of survival, and how long they were likely to continue without the disease progressing. Samples can be taken in “a matter of minutes”, with results in two to three days.
She added that the new insights, if borne out by further research, would mean clinicians could “make early changes of treatment from docetaxel to an alternative, which may significantly improve patients’ chances of long-term survival.”
The researchers took blood samples from 56 patients with advanced prostate cancer who were being treated at St Bartholomew’s Hospital in London.
The samples were taken over six to eight months — before the patients started docetaxel treatment, after their first dose of chemotherapy, before their fifth dose and once they had finished all doses — and 205 were collected in total.
The team looked for patterns in the data from men who responded to treatment or who did not, and whose cancer further advanced and at what speed.
They found that men were less likely to respond to docetaxel, the disease was more likely to recur or progress within three months and they were more likely to die within 18 months if more than six CTCs per 7.5ml of blood was detected before the first docetaxel dose. This compared to progression-free survival of 17 months and an overall survival time of three years for men with fewer than six CTCs per 7.5ml of blood.
The type of CTC detected may also play a role in predictions, the study suggests, while high numbers of CTCs towards the end of treatment predicted that men were more likely to suffer a rapid spread of cancer and an earlier death.
Davies said: “Using these patterns, we can apply them to future patients with the goal to predict whether they will respond to therapy and pre-emptively decide on the best course of action that will have maximal benefit. For instance, an increase in CTC numbers may indicate a lack of response to treatment. Furthermore, by monitoring the appearance of potentially drug-resistant CTCs, we can change treatment tactics early on and in a patient-personalised and timely manner.”
I'm convinced people are going to be surprised at the share price outperformance after FDA is achieved. I'm not just talking about the immediate impact either but what follows too. It will really throw the spotlight on Parsortix and it's capabilities. Major players, previously unaware, will be looking and saying who's this little company that have just achieved an FDA clearance and what exactly is it for ? Then they will conduct a thorough research, find out about all the possibilities for the system and discover the fact that an FDA for breast cancer is just the start with most other cancers to follow. They will be amazed and a big scramble may follow to get on board . All only imo of course.
Expect a share price rebound today.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, confirms that it has completed the work required to answer questions raised by FDA in its Additional Information Request and that a comprehensive response has been submitted to FDA as planned.
In line with industry best practice ANGLE does not intend to provide any further updates on communication with FDA regarding the submission whilst the regulatory process is as expected. ANGLE continues to anticipate a regulatory decision from FDA during H2 CY 2021*.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"We are pleased to have submitted a comprehensive response to FDA's request for additional information and look forward to FDA completing its substantive review."
Colon cancer detection has been confirmed.
https://www.proactiveinvestors.co.uk/companies/news/33798/angles-parsortix-device-confirmed-to-detect-colon-cancer--40272.html
Then why didn't vodafone do it ?
Some here need to keep up. Only just over 2 weeks ago this was announced. 'Shares in Dixons Carphone rose 11½ to 368.4p, a 6.9pc gain that sent the company to its highest level since the merger just under a month ago, as Vodafone said it was “enhancing its distribution partnership with Dixons Carphone from early next year and will not be extending its existing contract with Phones4U'. Far from losing network contracts you can expect strengthening. The dxns/cpw store presence and 'internet of things' concept is simply too big for them to be able to ignore imo.
It's 1 new share for every 6.45 Dixons approx. not for every 6. The .45 will make a bigger difference the more shares you have obviously.